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Purpose: We sought to maximize the antitumor effect of an anticancer vaccine based 
on genetically modified endothelial cells by combining it with the platelet-derived 
growth factor receptor inhibitor imatinib.
Materials and Methods: Human umbilical vein endothelial cells (HUVECs) were in-
fected with 10 MOI of Ad-CMV-mGMCSF to make anticancer vaccines. One million 
mouse bladder cancer cells (MBT-2) were subcutaneously inoculated in C3H mice. The 
experimental groups included the following: Group 1 (phosphate-buffered saline), 
Group 2 (anticancer vaccine and GM-CSF), Group 3 (imatinib), and Group 4 (anticancer 
vaccine, GM-CSF, and imatinib). Tumor growth and body weight were measured 
weekly. At 4 weeks, the tumors were immunostained with anti-CD31, and microvessel 
density (MVD) was measured. To evaluate the immunological mechanism of each treat-
ment, flow cytometry analysis of activated CD4 and CD8 cells was performed.
Results: At 4 weeks, the mean body weight of each group, excluding the extracted tumor 
weight, was not significantly different. Since week 3, the mean tumor volume in Group 
4 was the smallest among the treatment groups (p＜0.05), and a synergistic suppressive 
effect on tumor volume was observed in Group 4. The MVD in Group 4 was the most 
suppressed among the treatment groups (p＜0.05), and a synergistic anti-angiogenic 
effect was observed. Flow cytometry analysis revealed that activated CD4+ and CD8+ 
cells increased in Group 2 and decreased in Group 3 compared with the other groups.
Conclusions: The combination of genetically modified endothelial cell vaccines and im-
atinib showed a synergistic antiangiogenic effect in bladder cancer.
Key Words: Immunotherapy; Platelet-derived growth factor; Urinary bladder neoplasms
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 4 March, 2011
accepted 28 April, 2011
Corresponding Author:
Cheol Kwak
Department of Urology, Seoul National 
University Hospital, 101, Daehak-ro, 
Jongno-gu, Seoul 110-744, Korea
TEL: +82-2-2072-0817
FAX: +82-2-742-4665
E-mail: mdrafael@snu.ac.kr
This research was supported by a 
Research Foundation Grant funded by 
Seoul National University Hospital 
(04-2007-0920).
INTRODUCTION
The chemotherapeutic methotrexate, vinblastine, Adria-
mycin, and cisplatin (M-VAC) and gemcitabine, cisplatin 
(GP) regimens have been considered standard chemotoxic 
management for advanced bladder cancer because of the 
relatively high response rate observed during the early 
period. However, the long-term prognosis with the above 
regimens is poor, with a median survival period of 12 to 13 
months and a long-term survival rate of less than 5% [1,2]. 
Moreover, the side effects of standard cytotoxic chemo-
therapy cannot be ignored. Therefore, a new treatment mo-
dality is needed to achieve better anti-tumor effects with 
fewer side effects.
　Preclinical and clinical studies of cancer vaccines, such 
as viral vaccines, DNA vaccines using anti-tumor antigens 
and tumor-specific genes, genetically modified tumor vac-
cines, and vaccines that use dendritic cells, have been per-
formed. With the practice of instilling Bacillus Calmette- 
Guérin (BCG) intravesically to induce a local immune re-
action in superficial bladder cancer [3], the induction of a 
T-cell-mediated immune reaction specific to the cancer cell 
and activation of innate immunity, including natural killer 
cells, can be considered reasonable alternatives in the 
treatment of advanced bladder cancer. Cancer cells escape 
from immune surveillance via several mechanisms, in-Korean J Urol 2011;52:327-334
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cluding cancer-specific antigen alterations, suppression of 
molecules that present the antigen for MHC I, and active 
secretion of immunosuppressive substances [4]. Therefore, 
bypassing the cancer cells themselves and targeting the 
stromal cells that support the cancer cells may be a novel 
approach to overcoming the escape mechanism of cancer 
cells. Wei et al reported that a vaccine that targets the tu-
mor neovasculature has anti-tumor and preventive effects 
by activating the antibody reaction to angiogenetic-specific 
proteins, such as vascular endothelial growth factor re-
ceptor (VEGFR)-2 and αvβ3 integrin [5]. Since then, target-
ing stromal cells and the neovasculature as an approach 
to anti-tumor treatment has become an ongoing area of re-
search [6-8]. 
　Furthermore, various signal transduction pathways, in-
cluding the epidermal growth factor receptor (EGFR) path-
way, vascular endothelial growth factor (VEGF) pathway, 
and Ras/mitogen-activated protein kinase (Ras/MAPK) 
pathway, play significant roles in carcinogenesis and the 
progression of bladder cancer. Efforts to apply various ty-
rosine kinase inhibitors or monoclonal antibodies to the 
treatment of bladder cancer have been ongoing [9-11]. The 
VEGFR-2 signal transduction pathway is known as a cen-
tral component of tumor neoangiogenesis, and the role of 
the platelet-derived growth factor (PDGF) pathway in the 
angiogenesis of various tumors has also been shown in sev-
eral studies [12,13]. In the present study, we evaluated an-
ti-tumor effects by inhibiting neoangiogenesis by use of a 
combination of a genetically modified endothelial cell vac-
cine and imatinib, which inhibits PDGF receptor (PDGFR) 
inhibitor.
MATERIALS AND METHODS
1. Cell lines and culture
Human umbilical vein endothelial cells (HUVECs), of less 
than 20 passages, were purchased from the American Type 
Culture Collection (ATCC) for the production of an anti-
cancer vaccine and were grown in F-12K medium (ATCC, 
Manassas, VA, USA) supplemented with 10% fetal bovine 
serum (Gibco, Grand Island, NY, USA), 0.1 mg/ml heparin 
(Sigma-Aldrich, St. Louis, MO, USA), and 0.03 mg/ml endo-
thelial cell growth supplement (Sigma-Aldrich) in a hu-
midified atmosphere at 37
oC with 5% CO2.
　For the bladder cancer cell line, murine bladder tumor-2 
(MBT-2) cells induced by oral administration of N-[4-(5-ni-
tro-2-furyl)-2-thiazolyl]-foramide in C3H/HeN mice, pro-
vided by Prof. W.J. Kim, Department of Urology, Chungbuk 
National University of Medicine, were used. The MBT-2 
cells were grown in RPMI-1640 medium supplemented 
with 10% heat-inactivated fetal bovine serum (Gibco), 50 
units/ml penicillin, and 50 μg/ml streptomycin in a humidi-
fied atmosphere at 37
oC with 5% CO2.
2. Production of anticancer vaccine
Adenovirus transfected with murine GM-CSF (Ad-CMV- 
mGMCSF), provided by Dr. L.W. Chung, Department of 
Urology, University of Virginia, was used to produce the 
anticancer vaccine as previously reported [8]. 911 cells 
were infected with 10 multiplicity of infection (MOI) of virus 
and were kept frozen. Some of the 911 cells were cultured 
by using Cell Factory (Thermoscientific, Wilmington, DE, 
USA). When cell confluence reached 80%, the frozen 911 
cells were thawed three times, followed by centrifugation, 
and the supernatant was injected into the cultured 911 
cells. When a cytopathic effect was observed in more than 
90% of the cells, the cells were collected and kept frozen. 
High-concentration virus was refined by using CsCl gra-
dient centrifugation.
　HUVECs were plated in a six-well plate at a density of 
2x10
6 cells/well. Twenty-four hours after plating, the incu-
bation medium was replaced, and HUVECs were infected 
with 10 MOI of Ad-CMV-mGMCSF. Twelve hours after in-
fection, infected HUVECs (anticancer vaccines) were col-
lected and washed with phosphate-buffered saline (PBS) 
three times.
3. Treatment effect of anticancer vaccine and imatinib
After approval from the Seoul National University Hospital 
Institutional Animal Care and Use Committee (SNUH 
IACUC), the care of 4-week-old male C3H/HeN mice was 
performed according to the Guidelines for the Care and Use 
of Laboratory Animals in a Biological Safety Level 3 Labo-
ratory. The mice were inoculated with 1x10
6 MBT-2 cells 
diluted with 100 μl PBS subcutaneously. After 3 weeks, the 
mice were randomly assigned into four groups (n=3 per 
group): Group 1 (PBS injection group), Group 2 (anticancer 
vaccine＋GM-CSF injection group), Group 3 (imatinib in-
jection group), and Group 4 (anticancer vaccine＋imatinib
＋GM-CSF injection group). In Group 1, 100 μl PBS was in-
jected intraperitoneally weekly. In Group 2, anticancer 
vaccines and 1 μg of recombinant mouse GM-CSF diluted 
with 100 μl PBS were injected intraperitoneally weekly. In 
Group 3, 50 mg/kg imatinib (LC Laboratories, Woburn, 
MA, USA) diluted with 100 μl PBS was injected intra-
peritoneally daily. In Group 4, anticancer vaccines, re-
combinant mouse GM-CSF, and imatinib were injected in 
the same manner as above. To evaluate the safety of each 
treatment modality, we checked the body weight of the mice 
weekly. To evaluate the anti-tumor effect of each treat-
ment modality, the tumor volume was measured weekly. 
To calculate the tumor volume, one observer measured the 
long and short diameter of the tumor and calculated the tu-
mor volume by use of the following formula: 
　long diameter of tumor x (short diameter of tumor)
2x0.5. 
　After 4 weeks of treatment, the animals were euthanized 
with 5 mg/kg Zoletil, and the tumors and spleens were 
harvested.
4. Flow cytometry analysis of activated T-cells
The extracted spleen was crushed by using a tissue grinder 
and was washed with RPMI-1640 medium. After filtering Korean J Urol 2011;52:327-334
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FIG. 1. Mean body weights of mice during the treatment period. 
After 2 weeks of treatment, the mean body weights in Groups 2,
3, and 4 were less than in Group 1 (p＜0.05).
FIG. 2. Mean body weights of mice without the mass of the ex-
tracted tumor at week 4. When comparing body weights without
the mass of the extracted tumor at week 4, no significant differ-
ences were observed among the treatment groups (p=0.412).
FIG. 3. Mean tumor volumes during the treatment period. At 
weeks 3 and 4 of the treatment period, the mean tumor volume
in Groups 3 and 4 was significantly lower than in Group 1 (p
＜0.05). In Group 4, the mean tumor volume was the smallest 
among the treatment groups, and the differences were all statisti-
cally significant compared with the other groups (p＜0.05). The 
combination index of Group 4 at week 4 was 0.87.
the splenocytes in a 75 μm cell strainer, the filtered cells 
were centrifuged at 1,200 rpm for 10 min, and the super-
natant was discarded. The remaining cell pellets were 
washed with PBS and resuspended and cultured in 1 ml RBC 
lysis buffer (Sigma-Aldrich, St. Louis, MO, USA). Cultured 
cells were counted to 1x10
6 with an automated counter 
(Coulter Corporation, Miami, FL, USA) and suspended in 
50 μl FACS buffer (1x HBSS, 1.5% FBS, 1x sodium azide). 
The suspended cells were immunohistochemically stained 
with anti-mouse CD 69-PE, CD8a-FITC, and CD4-FITC (BD 
Biosciences, Franklin Lakes, NJ, USA) at 0
oC for 20 to 40 
min, followed by washing twice with PBS. After cell fixation 
using 400 μl of 3% formaldehyde, flow cytometry was per-
formed with a FACSCalibur
TM device (BD Biosciences).
5. Microvessel density assessment
The tumors were fixed in 10% neutral buffered formalin 
and embedded in paraffin. Tissue sections were cut to 4 μm 
thickness and immunohistochemically stained with CD31 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Accor-
ding to Gasparini’s criteria, the mean microvessel count of 
the 20 randomly selected areas was defined as the micro-
vessel density (MVD), which was expressed as the absolute 
number of microvessels per 0.74 mm
2 (200x field) [14]. To 
reduce observer-related variation, the counting of the mi-
crovessels was performed with a computer image analyzer.
6. Statistical analysis
SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA) was used for 
the statistical analysis. The results are expressed as means 
and standard deviations. Differences between treatment 
groups were examined by using the Kruskal-Wallis test 
and Mann-Whitney U test. Values of p＜0.05 were consid-
ered statistically significant. To evaluate the combination 
effect of the vaccine and imatinib, the Chou and Talalay 
combination index was calculated by using CalcuSyn soft-
ware (Biosoft, Cambridge, United Kingdom) [15]. If the 
combination index was less than 1, then we judged it as hav-
ing a synergistic effect. If it was equal to 1, then we judged 
it as having an additive effect. If it was greater than 1, then 
we judged it as having an antagonistic effect.
RESULTS
1. Anti-tumor effect and safety of vaccine and imatinib
Before the treatment, the mean body weight of each treat-
ment group showed no significant difference (Groups 1-4, 
respectively: 26.6±0.6 g, 26.6±0.4 g, 26.9±0.6 g, and 26.7± 
0.8 g; p=0.795). After 2 weeks of treatment, the mean body 
weights of Groups 2, 3, and 4 were less than that of Group 
1 (Fig. 1). However, when the body weight without the mass 
of the extracted tumor was compared at week 4, no significant 
differences were observed between the groups (Groups 1-4, 
respectively: 24.8±0.7 g, 19.1±1.9 g, 20.7±2.1 g, and 21.6± Korean J Urol 2011;52:327-334
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FIG. 4. Gross subcutaneous MBT-2 tumor in mice. These pictures were taken at week 4. The tumor size in Group 4 was the smallest
among the treatment groups (p＜0.05).
0.9 g; p=0.412) (Fig. 2). Therefore, we assumed that no sig-
nificant weight loss was caused by the anticancer vaccine 
or imatinib.
　At 3 weeks after tumor inoculation, the mean tumor vol-
umes in Groups 1 through 4 were 356.4±89.6 mm
3, 335.9± 
209.7 mm
3, 371.0±104.0 mm
3, 363.3±61.9 mm
3, respectively, 
and showed no significant differences between groups (p= 
0.996). After 4 weeks of treatment, the mean tumor volume 
in Group 2 was not significantly different from that in 
Group 1. However, after 3 and 4 weeks of treatment, the 
mean tumor volumes in Groups 3 and 4 were significantly 
smaller than in Group 1 (p＜0.05) (Fig. 3). In Group 4, which 
received the vaccine＋imatinib combination, the mean tu-
mor volume was the smallest among the treatment groups, 
and compared with the other groups, the differences were 
all statistically significant (p＜0.05) (Fig. 3, 4). The combi-
nation therapy in Group 4 had a 0.87 combination index, 
indicating a synergistic suppressive effect on tumor vol-
ume compared with both monotherapies.
2. Flow cytometry of activated T-cells
At the end of treatment, flow cytometry using splenocytes 
was performed to identify the composition of the immuno-
cytes. To identify the activated T-cells, we used CD69-PE 
as the detective marker. Helper T-cells (CD4) and cytotoxic 
T-cells (CD8), which play significant roles in cell-mediated 
immunity, were analyzed. In Groups 1 through 4, the pro-
portions of activated helper T-cells were 4.53%, 6.80%, 2.99%, 
and 5.80%, and the proportions of activated cytotoxic T-cells 
were 3.84%, 6.07%, 2.38%, and 4.95%, respectively (Fig. 5). 
In Groups 2 and 4, helper and cytotoxic T-cells were more 
activated than those in Group 1. However, in Group 3, which 
was treated with imatinib, helper and cytotoxic T-cells were 
less activated compared with Groups 1 and 2. In Group 4, 
which was treated with the vaccine＋imatinib combina-
tion, activated helper T-cells and cytotoxic T-cells were rel-
atively low compared with Group 2.
3. Microvessel density
The MVD observed at 20 sites randomly selected in each 
tumor section was 178.9±14.8, 148.5±9.3, 116.4±9.5, and 
69.0±7.6 in Groups 1 through 4, respectively, and the diffe-
rences between the groups were statistically significant (p
＜0.001) (Fig. 6, 7). Additionally, the combination index 
was 0.43 with combination therapy. Thus, we can assume 
that the combination therapy in Group 4 had a synergistic 
effect on the inhibition of angiogenesis.
DISCUSSION
Since Coley first suggested cancer treatment using the im-
mune system, continued efforts have been made to develop 
and produce an effective anticancer vaccine [16]. Typical 
anticancer vaccines have used tumor-associated antigen 
(TAA) and the tumor cells themselves for anti-tumor ef-
fects, and both mechanisms augment the immune surveil-
lance system against cancers. Tumor-infiltrating lympho-
cytes (TILs) are believed to play an important role in the 
immunologic attack on tumors. In various solid tumors, 
several studies on the positive correlation between the 
number of TILs and favorable prognosis have shown that 
TILs play a central role in the immune surveillance system 
of the host against the tumor [17-19]. TILs are mainly pro-
duced by the cell-mediated immune reaction, and they in-
vade and induce tumor cell death. However, because tumor 
cells are genetically unstable and frequently mutate, anti-Korean J Urol 2011;52:327-334
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FIG. 5. Flow cytometry analysis of (A) 
helper T-cells (CD4＋  cells) and (B) cy-
totoxic T-cells (CD8＋  cells). The dots in
the upper right quadrant represent the
number of activated T-cells. More acti-
vated helper and cytotoxic T-cells were
observed in Groups 2 and 4 than in 
Group 1. However, in Group 3, which 
was treated with imatinib, fewer acti-
vated helper and cytotoxic T-cells were
observed compared with Groups 1 and
2. In Group 4, which was treated with 
vaccine and imatinib, activated helper
T-cells and cytotoxic T-cells were rela-
tively low compared with Group 2.
cancer vaccines that use TAAs and the tumor cells them-
selves have not shown great clinical success. No successful 
results have been found in Phase 3 studies of melanoma, 
although the accumulated data regarding TAAs in melano-
ma are considerable. In other types of tumors, similar to 
melanoma, successful data have not been found [19]. As a 
result, targeting stromal cells while bypassing the cancer 
cells may be an approach to overcoming the escape mecha-
nism of cancer cells and is an area of extensive ongoing 
research.
　Folkman et al reported the importance of neoangiogenesis 
in tumor growth [20], and targeting the neovasculature of 
tumors as an anti-tumor approach has been attempted. 
Wei et al reported that endothelial cell vaccines extracted 
from humans and calves, when applied to several lines of 
mouse cancer cells, showed good preventive and treatment 
effects [5]. We previously reported that an endothelial cell 
vaccine, genetically modified to reinforce the immune re-Korean J Urol 2011;52:327-334
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FIG. 6. Analysis of microvessel density (MVD) of MBT-2 tumor. 
The differences between groups were statistically significant (p
＜0.001). The combination index was 0.43 with the combination
therapy (Group 4).
FIG. 7. Photomicrographs depicting tumor microvessels (CD31 immunohistochemical staining, x200). After immunohistochemical 
staining with CD31, the microvessels were stained brown. Microvessels decreased markedly in Group 4, moderately in Group 3, and
slightly in Group 2.
action, showed anti-tumor effects in a bladder cancer cell 
line by inhibiting neoangiogenesis [8]. There was no sigini-
ficant difference in tumor growth between control and 
HUVECs only. However, the growth of the tumor in the 
group treated with anticancer vaccine was significantly 
suppressed compared with that in the control and HUVECs 
only groups. Also, MVD in the group treated with anticancer 
vaccine was significantly lower than in the control and 
HUVECs only groups. In flow cytometry analysis, activated 
CD4 and CD8 cells were increased in the group treated with 
anticancer vaccine compared the control and HUVECs only 
groups. 
　In the present study, to reinforce the immune reaction 
by using an endothelial cell vaccine, we additionally used 
recombinant GM-CSF. Generally, GM-CSF is believed to 
consolidate the immune reaction by stimulating Langerhans 
cells and dendritic cells [21]. GM-CSF can also suppress the 
immune reaction, depending on the dosage. Reali et al re-
ported that the tumor-suppressive effect of an anticancer 
vaccine increased in nude mice when daily, repeated 20 μg 
recombinant GM-CSF was administered intraperitoneally 
for 4 days by increasing activated dendritic cells in lymph 
nodes and activating CD4＋  T-cells and CD8＋  T-cells [22]. 
However, other studies have reported immunological sup-
pression with high concentrations of GM-CSF, which is 
caused by the emergence of myeloid suppressor cells [23]. 
In the present study, we sought to obtain more powerful an-
ti-tumor effects with the vaccines through weekly intra-
peritoneal administration of low-dose GM-CSF. Flow cy-
tometry analysis revealed that Group 2, which was treated 
with vaccine, had elevated activated helper T-cells (CD4) 
and cytotoxic T-cells (CD8). The combination of the anti-
cancer vaccine and GM-CSF, which was used to assist the Korean J Urol 2011;52:327-334
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vaccine-induced immunological reaction, suppressed an-
giogenesis by augmenting the immune reaction. Additio-
nally, we can confirm the difference from the previously re-
ported anticancer vaccines that targeted endothelial cells 
[5,6] because our endothelial cell vaccine suppressed tu-
mors by inducing the cell-mediated immune reaction.
　In the present study, the endothelial cell vaccine＋im-
atinib combination had a synergistic effect in decreasing 
MVD and suppressing tumor growth. Imatinib, which 
blocks PDGFR-α, PDGFR-β, c-kit, and bcr-abl, was the first 
tyrosine kinase inhibitor approved for clinical use [24]. 
Therefore, we can infer that both anti-angiogenesis induced 
by PDGFR inhibition and the alteration of the immuno-
logical environment by inhibiting bcr-abl contribute to the 
synergistic effect of the combination therapy. The VEGF 
pathway is believed to play a central role in tumor neo-
angiogenesis. However, recent studies have suggested that 
the PDGF pathway also plays a very important role in tumor 
angiogenesis [12,13]. In bladder cancer carcinogenesis, the 
significance of the PDGF pathway is not well known. How-
ever, Kassouf et al reported that PDGFR-β overexpression 
in a bladder cancer cell line is resistant to gefitinib [9], and 
Black et al suggested that PDGFR inhibition is an im-
portant treatment option, based on evidence of anti-tumor 
effects of PDGFR-β inhibition [25]. Moreover, imatinib has 
been shown to suppress the activation of T-cells and deplete 
lymphocytes by inhibiting bcr-abl [26,27]. In the present 
study, Group 3, which was treated with imatinib, exhibited 
a suppression of activation of helper T-cells and cytotoxic 
T-cells. In Group 4, which was treated with vaccine and im-
atinib, activated helper T-cells and cytotoxic T-cells were 
relatively low compared with Group 2. Despite the immuno-
logic-suppressive effect of imatinib, the synergistic effect 
on anti-angiogenesis and tumor growth is supported by a 
previous report, in which immunomodulation caused by 
lymphocyte depletion strengthened the immune reaction 
to cancer cell-specific antigen [28]. Chemotherapy gen-
erally inhibits the mitosis of lymphocytes and suppresses 
immune function. However, traditional cytotoxic chemo-
therapy activates the immune system by various mecha-
nisms. Wrzesinski et al reported that the depletion of lym-
phocytes caused by cytotoxic agents promoted the differen-
tiation of T-cells to memory cells and strengthened the anti-
gen-specific immune reaction in cancer cells [29]. Larmonier 
et al reported that imatinib significantly enhanced anti-
tumor immune responses to dendritic cell-based immuni-
zation and their results support previous studies indica-
ting that imatinib may improve responses to tumor-specific 
vaccination [30]. In the present study, we can assume that 
the synergistic effect of combination therapy on anti-angio-
genesis was induced by augmenting a specific immune re-
action in endothelial cells with the lymphocyte-suppressive 
action of imatinib.
CONCLUSIONS
In the present study, an anticancer vaccine that used ge-
netically modified endothelial cells and GM-CSF inhibited 
neoangiogenesis in urinary bladder cancer via a T-cell- 
mediated immune reaction. The PDGFR inhibitor im-
atinib suppressed angiogenesis of the tumor, and the im-
atinib＋anticancer vaccine combination had a synergistic 
effect on anti-angiogenesis. The method we used in the pre-
sent study was not tumor-specific and may be applicable 
to many different types of tumors. Additionally, the inhibition 
of angiogenesis induced by using a different approach while 
using an endothelial cell vaccine to overcome immuno-
logical drawbacks differentiates this study from previous 
studies. Although additional research is needed, we believe 
that the method we used may become a basis for future che-
motherapeutic regimens.
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